In a report issued on July 29, Jason Kolbert from Dawson James maintained a Hold rating on Adamis Pharma (ADMP – Research Report). The company's shares closed last Friday at $0.38, close to its 52-week low of $0.31. According to TipRanks.com, Kolbert is a 1-star analyst with an average return of -2.0% and a 34.7% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Citius Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Adamis Pharma. See the top stocks recommended by analysts >> Adamis Pharma's market cap is currently $56.
https://www.tipranks.com/news/blurbs/dawson-james-sticks-to-its-hold-rating-for-adamis-pharma-admp?utm_source=advfn.com&utm_medium=referral
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Adamis Pharmaceuticals Charts.
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Adamis Pharmaceuticals Charts.